Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
global blood cancer drugs market

Global Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region (North America - U.S., Canada; Europe - UK, Germany, France; Asia-Pacific - China, Japan, India; Latin America - Brazil, Mexico; Middle East & Africa)]: Market Size & Forecast, 2017 – 2025

Published: Apr 2018
Pages: 90
Format: PDF
Report ID: PM1238
Buy Now

Report Summary

The global blood cancer drugs market is valued at USD 24.3 billion in 2017 and is anticipated to grow at a CAGR of 11.1% during the forecast period. The combination drug regimens in treating various kinds of blood cancer have recently taken off. These combinations need to be synergistic without overlapping toxicities by understanding the type of drugs to be combined. The recently developed blood cancer drugs look highly promising and is poised to move up the treatment paradigm in the future. Despite of high price and small number of patients, there is a steady flow which is creating opportunities in the lucrative market.

This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the favored drugs in trials for treating multiple myeloma. Furthermore, rising partnerships and alliances between the companies for promoting the use of drugs, and increasing R&D spends in platform technologies by the players across the continuum are some of the factors that would drive the growth of the blood cancer drugs market.

The majority of the biopharmaceutical companies is focused on developing new combination drugs for the treatment of blood cancer. Recently, AbbVie is focusing on combination of Imbruvica and Venclexta which is being studied for the treatment of CLL and MCL.

North America Blood Cancer Drugs Market Share by Treatment Approaches, 2017 - 2025

North America Blood Cancer Market, By Treatment Approach, 2017 - 2026  (USD Billion)

Note: Inside circle depicts data for 2017 & outside circle depicts data for 2025

Type of Blood Cancer Insights

Blood cancer starts within the bone marrow, where the blood is composed. The stem cells in the bone marrow mature to develop three types of cells viz. red blood cells, white blood cells, and platelets. Blood cancer is characterized by the uncontrolled growth of cancerous cell that displace the normal functional cells. These cancerous cells affect the function of normal blood. Blood cancer is, basically, bifurcated as Leukemia and Lymphoma.

The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market.

Type of Drugs Insights

On the basis of drugs, the global blood cancer drugs market is segmented into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. Due to the drug effectiveness, the demand for personalized cancer drugs is expected to increase significantly during the forecast period. Increasing number of leukemia suffering patients is generating more demand for blood cancer drugs. As many of the leukemia cases are undetected in early stage, the emphasis is on effective drugs for recovery.

Treatment Approaches Insights

Blood cancer drugs are segmented according to the treatment approaches as chemotherapeutic, targeted therapies, and immunotherapies. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world. Nonetheless, the comparatively high price and high risk side effects by the use of these drugs would impede the market for chemotherapeutic drugs in the future.

In addition, immunotherapies are likely to grow as an alternative for chemotherapy over the period, due to lesser side effects and improved efficiency. This particular segment is anticipated to enhance the growth of the global blood cancer drugs market in the forecast period.

Sample Table

North America Blood Cancer Market, By Treatment Approach, 2017 - 2026  (USD Billion)

North America Blood Cancer Market, By Treatment Approach, 2017 - 2026  (USD Billion)

Regional Insights  

North America holds a major share for blood cancer drugs market, which is basically driven by the increasing demand for the drugs in the U.S. market with the availability of advanced healthcare facilities, and increasing number of blood cancer patients. Furthermore, the presence of major pharmaceutical companies, increased investment on R&D in the region, and increasing awareness & preferences for the immunotherapies will also spur the market of blood cancer drug in North America during the forecast period.

Similarly, Europe holds the second largest market share of blood cancer drugs. The European blood cancer drugs market is driven by effective policies that promote the awareness about blood cancer, increased government investment for improving the healthcare facilities, and high rate of diagnosis of blood cancer at initial stages. Moreover, Asia-Pacific would observe a lucrative growth in the blood cancer drugs market. Increased government initiatives for creating awareness about blood cancer, improved healthcare facilities for treating blood cancer, and the availability of low cost generic and biosimilar drugs are expected to drive Asia-pacific blood cancer drugs market during the forecast period.

Competitive Landscape

Major firms are focusing on small firms with a working methodology of securing the end goal to manage position in the market and are associated with mergers and acquisitions, key joint efforts, and novel item advancement to pick up profit share in the business. Some major key players in global blood cancer drugs market includes Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc., Roche Holding AG, Celgene Corporation, Merck and Company, Novartis AG, and GlaxoSmithKline Pharmaceuticals Ltd. among others

Key questions answered by the report

  • What is the current market size and forecasts of global blood cancer drugs market
  • What is the market opportunity for the blood cancer treatment market
  • How big is the market size for treating subtypes of blood cancer market
  • How much will the North America blood cancer drugs market be worth by 2025
  • How big is the market size of chemotherapeutic treatment approach globally
  • What are the available opportunities and who are the top market players in this segment
  • Which new drugs are gaining approvals for treating blood cancer

Table of Contents

  1. Overview and Scope
    1. Research goal & scope
    2. Research assumptions
    3. Research methodology
      1. Primary data sources
      2. Secondary data sources
    4. Key take-away
    5. Stakeholders
  2. Executive Summary
    1. Market definition
    2. Market segmentation
  3. Blood cancer drugs market Insights
    1. Blood Cancer Drug – Industry snapshot
      1. Leading Companies
      2. Emerging Companies & Technologies Platform
      3. Key Companies to Watch
    2. Blood Cancer Drug - Ecosystem analysis
      1. Disease overview
      2. Commercial Landscape
      3. Future Treatment Paradigm
    3. Blood cancer drugs market Dynamics
      1. Blood Cancer Drug – Market Forces
        1. Blood cancer drugs market Driver Analysis
        2. Blood cancer drugs market Restraint/Challenges analysis
        3. Blood Cancer Market Opportunity Analysis
      2. Industry analysis - Porter's five forces
        1. Bargaining power of supplier
        2. Bargaining power of buyer
        3. Threat of substitute
        4. Threat of new entrant
        5. Degree of competition
      3. Blood cancer drugs market PEST Analysis, 2017
      4. Blood cancer drugs market Value Chain Analysis
      5. Blood Cancer Drug Industry Trends
      6. Competitive Ranking Analysis
  4. Blood cancer drugs market Size and Forecast, 2017-2025 by Blood Cancer Type
    1. Key Findings
    2. Lymphoma
      1. Hodgkin Lymphoma
      2. Non-Hodgkin Lymphoma
        1. B-cell Lymphoma
          1.  Diffuse Large B-Cell Lymphoma
          2. Mantle Cell Lymphoma
          3. Burkitt Lymphoma
          4. Central Nervous System Lymphoma
        2. T-cell Lymphoma
          1. Precursor T-Lymphoblastic Lymphoma
          2. Peripheral T-Lymphoma
      3.  Leukemia
        1. Acute Myeloid Leukemia
        2. Chronic Myeloid Leukemia
        3. Acute Lymphoblastic Leukemia
        4. Chronic Lymphocytic Leukemia
      4. Myeloma
        1. Multiple Myeloma
  5. Blood cancer drugs market Size and Forecast, 2017-2025 by Drugs
    1. Rituaxan/Mabthera (Rituximab)
    2. Gleevac/Glivec (Imatinib)
    3. Revlimid (Lenalidomide)
    4. Velcade (Bortezomib)
    5. Tasigna (Nilotinib)
    6. Pomalyst (Pomalidomide)
    7. Vidaza (Azacitidine)
    8. Kyprolis (Carfilzomib)
    9. Adcetris (Brentuximab Vedotin)
    10. Others
  6. Blood cancer drugs market Size and Forecast, 2017-2025 by Treatment Approaches
    1. Key Findings
    2. Chemotherapeutic
    3. mAbs/Targeted Therapies
    4. Immunotherapeutic
  7. Blood cancer drugs market Size and Forecast, 2017-2025 by Region
    1. Key Findings
    2. North America
      1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
      2. Blood Cancer Drugs Market by drugs, 2017 – 2025
      3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      4. U.S.
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      5. Canada
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
    3. Europe
      1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
      2. Blood Cancer Drugs Market by drugs, 2017 – 2025
      3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      4. UK
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      5. Germany
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      6. France
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
    4. Asia-Pacific
      1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
      2. Blood Cancer Drugs Market by drugs, 2017 – 2025
      3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      4. China
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      5. Japan
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      6. India
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
    5. Latin America
      1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
      2. Blood Cancer Drugs Market by drugs, 2017 – 2025
      3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      4. Brazil
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
      5. Mexico
        1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
        2. Blood Cancer Drugs Market by drugs, 2017 – 2025
        3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
    6. Middle East & Africa
      1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025
      2. Blood Cancer Drugs Market by drugs, 2017 – 2025
      3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025
  8. Company Profiles
    1. Johnson & Johnson Inc.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    2. Amgen Inc.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    3. Bayer AG.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    4. Pfizer Inc.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    5. Eli Lily & Co.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    6. AstraZeneca
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    7. AbbVie Inc.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    8. Roche Holding AG
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    9. Celgene Corporation.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    10. Merck and Company
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    11. Novartis AG.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments
    12. GlaxoSmithKline Pharmaceuticals Ltd.
      1. Overview
      2. Financials
      3. Product Benchmarking
      4. Recent Developments

Report Content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • SWOT Analysis
  • Porter’s analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Overview
    • Financials
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecasts from 2017 – 2025
  • Market revenue estimates for blood cancer type up to 2025
  • Market revenue estimates for drugs up to 2025
  • Market revenue estimates for treatment approaches to 2025
  • Regional market size and forecast for blood cancer type segment up to 2025
  • Regional market size and forecast for drugs segment up to 2025
  • Regional market size and forecast for treatment approaches segment up to 2025
  • Company financials

At Polaris Market Research, we engage in the most iterative and comprehensive research methodology which primarily focuses on providing the most accurate market forecasts and research data content enabling you to gain unprecedented business acumen. The company chiefly utilizes top-down and bottom up approaches, for both qualitative market estimations and market segmentations. We boast of our expertise in skillfully using data triangulation for looking at the market from the 3 main perspectives of primary data mining, dedicated statistical model and framework, data validation from primary sources.

The groundwork of data mining is initiated by picking up the raw data of markets analysis through sets of reliable and validated websites, analyst reviews and press releases; whitepapers, reputed paid databases such as Factiva, Hoovers, OneSource etc. and from hordes of data consolidated in our repository. Technical data and trends are collaborated through in-depth surveys and trade journals. Pricing trends and industry dynamics are gauged from authenticated sources.

This raw data is analyzed and identified in detail for the market impact. The market estimation and forecasts are derived through specific data simulation models. A collaborative amalgamation for market forecast and estimation is performed through technology analysis, economic tools, and domain expertise. Ideally a bottom-up approach is preferred for obtaining global market estimates and to derive an expected market growth rate.

The analyzed data, assumptions and findings are validated through primary sources by conducting exhaustive primary interviews including telephonic discussions, face-to face discussions and focused group discussions. Majority of the key industry participants for our primary discussions include C-level executives, supply-chain participants, distributors and domain experts, key customers and B2B clients.

 

Request For customization

Speak to Analyst

Inquire Before Buying

Request for Free Sample

Request for Free Sample